|
1
|
Vigneswaran N and Williams MD:
Epidemiologic trends in head and neck cancer and aids in diagnosis.
Oral Maxillofac Surg Clin North Am. 26:123–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brennan JA, Boyle JO, Koch WM, Goodman SN,
Hruban RH, Eby YJ, Couch MJ, Forastiere AA and Sidransky D:
Association between cigarette smoking and mutation of the p53 gene
in squamous-cell carcinoma of the head and neck. N Engl J Med.
332:712–717. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
D'Souza G, Kreimer AR, Viscidi R, Pawlita
M, Fakhry C, Koch WM, Westra WH and Gillison ML: Case-control study
of human papillomavirus and oropharyngeal cancer. N Engl J Med.
356:1944–1956. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haddad RI and Shin DM: Recent advances in
head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Poeta ML, Manola J, Goldwasser MA,
Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D,
Saunders J, et al: TP53 mutations and survival in squamous-cell
carcinoma of the head and neck. N Engl J Med. 357:2552–2561. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin D, Abba MC, Molinolo AA,
Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG and
Gutkind JS: The head and neck cancer cell oncogenome: A platform
for the development of precision molecular therapies. Oncotarget.
5:8906–8923. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Algazi AP and Grandis JR: Head and neck
cancer in 2016: A watershed year for improvements in treatment? Nat
Rev Clin Oncol. 14:76–78. 2017. View Article : Google Scholar
|
|
10
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bar-Ad V, Palmer J, Yang H, Cognetti D,
Curry J, Luginbuhl A, Tuluc M, Campling B and Axelrod R: Current
management of locally advanced head and neck cancer: The
combination of chemotherapy with locoregional treatments. Semin
Oncol. 41:798–806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hartner L: Chemotherapy for oral cancer.
Dent Clin North Am. 62:87–97. 2018. View Article : Google Scholar
|
|
14
|
Sano D, Xie TX, Ow TJ, Zhao M, Pickering
CR, Zhou G, Sandulache VC, Wheeler DA, Gibbs RA, Caulin C and Myers
JN: Disruptive TP53 mutation is associated with aggressive disease
characteristics in an orthotopic murine model of oral tongue
cancer. Clin Cancer Res. 17:6658–6670. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nuth M, Guan H, Zhukovskaya N, Saw YL and
Ricciardi RP: Design of potent poxvirus inhibitors of the
heterodimeric processivity factor required for viral replication. J
Med Chem. 56:3235–3246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nuth M, Guan H, Xiao Y, Kulp JL III,
Parker MH, Strobel ED, Isaacs SN, Scott RW, Reitz AB and Ricciardi
RP: Mutation and structure guided discovery of an antiviral small
molecule that mimics an essential C-Terminal tripeptide of the
vaccinia D4 processivity factor. Antiviral Res. 162:178–185. 2019.
View Article : Google Scholar
|
|
17
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koh SB, Mascalchi P, Rodriguez E, Lin Y,
Jodrell DI, Richards FM and Lyons SK: A quantitative FastFUCCI
assay defines cell cycle dynamics at a single-cell level. J Cell
Sci. 130:512–520. 2017.
|
|
19
|
Sakaue-Sawano A, Kurokawa H, Morimura T,
Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi
H, et al: Visualizing spatiotemporal dynamics of multicellular
cell-cycle progression. Cell. 132:487–498. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaufmann SH, Desnoyers S, Ottaviano Y,
Davidson NE and Poirier GG: Specific proteolytic cleavage of
poly(ADP-ribose) polymerase: An early marker of
chemotherapy-induced apoptosis. Cancer Res. 53:3976–3985.
1993.PubMed/NCBI
|
|
21
|
Chaitanya GV, Alexander JS and Babu PP:
PARP-1 cleavage fragments: Signatures of cell-death proteases in
neurodegeneration. Cell Commun Signal. 8:312010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Somers KD, Merrick MA, Lopez ME, Incognito
LS, Schechter GL and Casey G: Frequent p53 mutations in head and
neck cancer. Cancer Res. 52:5997–6000. 1992.PubMed/NCBI
|
|
24
|
Giaccia AJ and Kastan MB: The complexity
of p53 modulation: Emerging patterns from divergent signals. Genes
Dev. 12:2973–2983. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bode AM and Dong Z: Post-translational
modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deyoung MP and Ellisen LW: p63 and p73 in
human cancer: Defining the network. Oncogene. 26:5169–5183. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sniezek JC, Matheny KE, Westfall MD and
Pietenpol JA: Dominant negative p63 isoform expression in head and
neck squamous cell carcinoma. Laryngoscope. 114:2063–2072. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nylander K, Coates PJ and Hall PA:
Characterization of the expression pattern of p63α and δnp63α in
benign and malignant oral epithelial lesions. Int J Cancer.
87:368–372. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bisso A, Collavin L and Del Sal G: p73 as
a pharmaceutical target for cancer therapy. Curr Pharm Des.
17:578–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
el-Deiry WS, Tokino T, Velculescu VE, Levy
DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and
Vogelstein B: WAF1, a potential mediator of p53 tumor suppression.
Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Georgakilas AG, Martin OA and Bonner WM:
p21: A two-faced genome guardian. Trends Mol Med. 23:310–319. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leemans CR, Braakhuis BJM and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View Article : Google Scholar
|
|
33
|
Bailly C, Thuru X and Quesnel B: Combined
cytotoxic chemotherapy and immunotherapy of cancer: Modern times.
NAR Cancer. 2:zcaa0022020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Knox RJ, Friedlos F, Lydall DA and Roberts
JJ: Mechanism of cytotoxicity of anticancer platinum drugs:
Evidence that cis-di amminedichloroplatinum(II) and
cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(ii) differ only
in the kinetics of their interaction with dna. Cancer Res.
46:1972–1979. 1986.PubMed/NCBI
|
|
35
|
Boeckman HJ, Trego KS and Turchi JJ:
Cisplatin sensitizes cancer cells to ionizing radiation via
inhibition of nonhomologous end joining. Mol Cancer Res. 3:277–285.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grem JL: 5-Fluorouracil: Forty-plus and
still ticking. A review of its preclinical and clinical
development. Invest New Drugs. 18:299–313. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bossi P, Resteghini C, Paielli N, Licitra
L, Pilotti S and Perrone F: Prognostic and predictive value of EGFR
in head and neck squamous cell carcinoma. Oncotarget.
7:74362–74379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pendleton KP and Grandis JR:
Cisplatin-based chemotherapy options for recurrent and/or
metastatic squamous cell cancer of the head and neck. Clin Med
Insights Ther. 2013:10.4137/CMT.S10409. 2013.PubMed/NCBI
|
|
40
|
Johnstone RW, Frew AJ and Smyth MJ: The
TRAIL apoptotic pathway in cancer onset, progression and therapy.
Nat Rev Cancer. 8:782–798. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu GS, Burns TF, McDonald ER III, Jiang W,
Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al:
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor
gene. Nat Genet. 17:141–143. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sheikh MS and Fornace AJ Jr: Death and
decoy receptors and p53-mediated apoptosis. Leukemia. 14:1509–1513.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hainaut P and Hollstein M: p53 and human
cancer: The first ten thousand mutations. Adv Cancer Res.
77:81–137. 2000. View Article : Google Scholar
|
|
44
|
Liu DP, Song H and Xu Y: A common gain of
function of p53 cancer mutants in inducing genetic instability.
Oncogene. 29:949–956. 2010. View Article : Google Scholar :
|
